Related Experiment Videos
Biocontainment design considerations for biopharmaceutical facilities
1SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
Journal of Industrial Microbiology
|July 1, 1993
Summary
This article provides biocontainment design recommendations for biopharmaceutical manufacturing. It focuses on Biosafety Level 2--Large-Scale facilities and regulatory interpretation for effective physical containment.
Area of Science:
- Biopharmaceutical Manufacturing
- Biosafety Engineering
- Regulatory Compliance
Background:
- Biopharmaceutical production requires stringent biocontainment measures to ensure safety.
- Existing regulations guide the design of facilities for handling biological agents.
- Interpretation of these regulations can vary, impacting facility design.
Purpose of the Study:
- To outline biocontainment design considerations for biopharmaceutical manufacturing.
- To analyze industry's interpretation and application of relevant regulations.
- To provide specific design recommendations for Biosafety Level 2--Large-Scale (BSL-2 Large-Scale) facilities.
Main Methods:
- Review of National Institutes of Health (NIH) Guidelines for Biosafety Level 2.
- Analysis of regulatory documents pertaining to biopharmaceutical manufacturing.
- Development of design recommendations based on BSL-2 principles and large-scale operations.
Main Results:
- Key biocontainment design elements for BSL-2 Large-Scale facilities identified.
- Common industry interpretations and potential challenges in regulatory application highlighted.
- Specific, actionable design recommendations provided for physical containment.
Conclusions:
- Effective biocontainment in biopharmaceutical manufacturing relies on clear regulatory interpretation and tailored design.
- Implementing BSL-2 Large-Scale recommendations enhances safety and compliance.
- Adherence to specific design considerations is crucial for successful biopharmaceutical production environments.